Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension

Medical Hypotheses

Volumn 72, Issue 6, 2009, Pages 713-719

  Tofovic, Stevan P ^a   Jackson, Edwin K ^a   Rafikova, Olga ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIPROPYL 8 (4 SULFOPHENYL)XANTHINE; ADENOSINE DEAMINASE; ENDOTHELIN RECEPTOR ANTAGONIST; INOSINE; NITRIC OXIDE; PENTOSTATIN; SILDENAFIL;

ARTICLE; BLOOD CLOT LYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ERYTHROCYTOSIS; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAVASCULAR HEMOLYSIS; LIVER TOXICITY; NONHUMAN; PRIAPISM; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SICKLE CELL ANEMIA; VASOCONSTRICTION;

ADENOSINE; ADENOSINE DEAMINASE; HEMOLYSIS; HUMANS; HYPERTENSION, PULMONARY; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 62949184781     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.12.043     Document Type: Article

References (81)

1. Collins F.S., and Orringer E.P. Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 73 (1982) 814-821
2. Morris C.R., Kuypres F.A., Kato G.J., Lavrisha L., Larkin S., Singer T., et al. Hemolysis-associated pulmonary hypertension in thalassemia. Ann NY Acad Sci 1054 (2005) 481-485
3. Verresen D., De Backer W., Van Meerbeeck J., Neetens I., Van Marck E., and Vermeire P. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?. Eur Respir J 4 (1991) 629-631
4. Heller P.G., Grinberg A.R., Lencioni M., Molina M.M., and Roncoroni A.J. Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest 102 (1992) 642-643
5. Castro O.L., Hoque M., and Brown B.D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 101 (2003) 1257-1261
6. Wood K.C., Hsu L.L., and Gladwin M.T. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free Radical Biol Med 44 (2008) 1506-1528
7. Sharff A.J., Wilson D.K., Chang Z., and Quiocho F.A. Refined 2.5 Å structure of murine adenosine deaminase at pH 6.0. J Mol Biol 226 (1992) 917-921
8. Daddona P.E., and Kelly W.N. Human adenosine deaminase: purification and subunit structure. J Biochem 252 (1997) 110-115
9. Zhu O., Matherne G.P., Curnish R.R., Tribble C.G., and Bernie R.M. Effect of adenosine deaminase on cardiac interstitial adenosine. Am J Physiol 263 (1992) H1322-H1326
10. Castro O., Kato G.J., Sachdev N., et al. The sickle cell-pulmonary hypertension study: ECHO findings at two-years of follow up. Blood 106 1 l (2005) 95a
11. Sutton L.L., Castro O., Cross D.J., Spencer J.E., and Lewis J.F. Pulmonary hypertension in sickle cell disease. Am J Cardiol 74 (1994) 626-628
12. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004) 886-895
13. Haque A.K., Gokhale S., Rampy B.A., Adegboyega P., Duarte A., and Saldana M.J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 33 (2002) 1037-1043
14. De Castro L.M., Jonassiant J.C., Graham F.L., Ashley-Koch A., and Tellen M.J. Pulmonary hypertension in SS, SC and S, thalassemia: prevalence, associated clinical syndromes, and mortality. Blood 104 (2004) 462a
15. Ataga K.I., Moore C.G., Jones S., et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol 134 (2006) 109-115
16. Machado R.F., and Castro O. Sickle cell disease-associated pulmonary hypertension: overview of clinical manifestations and emerging therapeutic options. Adv Pulm Hypertens 6 (2007) 16-23
17. Rother R.P., Bell L., Hillmen P., and Galdwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293 (2005) 1653-1662
18. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 8 (2002) 1383-1389
19. Morris C.R., Kato G.J., Poljakovic M., Wang X., Blackwelder W.C., Sachdev V., et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294 (2005) 81-90
20. Gladwin M.T., and Kato G. Hemolysis-associated endothelail dysfunction and pulmonary hypertension, an emerging cause of death in the hemoglobinopathies. Adv Pulm Hypertens 6 (2007) 23-30
21. Gladwin M.T., Sachdev V., Jison M.L., Shizukuda Y., Plehn J.F., Minter K., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 (2004) 886-895
22. Taylor J.G., Nolan V.G., Mendelsohn L., Kato G.J., Gladwin M.T., and Steinberg M.H. Chronic hyper-hemolysis is sickle cell anemia: association of vascular complication and mortality with less frequent vasoocclusive pain. PLoS ONE 3 5 (2008) e2095
23. Hsu L.L., Champion H.C., Campbell-Lee S.A., Bivalacqua T.J., Manci E.A., Diwan B.A., et al. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109 (2007) 3088-3098
24. Headrick J.P., and Berne R.M. Endothelium dependent- and independent-relaxations to adenosine in guinea pig aorta. Am J Physiol 259 (1990) H62-H67
25. Steinhorn R.H., Morin F.C., Van Wylen D.G.L., Gugino S.F., Giese J.A., and Russell E.C. Endothelium dependent relaxations to adenosine in juvenile rabbit pulmonary arteries and veins. Am J Physiol 266 (1994) H2001-H2006
26. Vials A., and Burnstock G. A2-purinoceptor-mediated relaxation in the guinea-pig coronary vasculature: a role for nitric oxide. Br J Pharmacol 109 (1993) 424-429
27. Tabrizchi R., and Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther 91 (2001) 133-147
28. Jackson E.K. Adenosine: a physiological brake on renin release. Annu Rev Pharmacol Toxicol (1991) 31-1-31-35
29. Rongen G.A., Lenders J.W., Lambrou J., et al. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension 27 (1996) 933-938
30. Stadler B., Phillips J., Toyoda Y., Federman M., Levitsky S., and McCully J.D. Adenosine-enhanced ischemic preconditioning modulates necrosis and apoptosis: effects of stunning and ischemia-reperfusion. Ann Thorac Surg 72 (2001) 555-563
31. Gazonin L.M., Laubach V.E., Mulloy D.P., Bellizzi A., Unger E.B., Linden J., et al. Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg 135 (2008) 156-165
32. Sharma A.K., Yang Z., Linden J.M., Kron I.L., and Laubach V.E. Attenuation of ischemia-reperfusion injury by adenosine A2A receptor activation in a buffer-perfused mouse lung model. Am J Res Crit Care Med 117 Abstract issue (2008) A80
33. Zhao M., Polanowska-Grabowska R., and Linden J.M. Adenosine 2A receptor activation inhibits leukocyte infiltration during lung ischemia-reperfusion injury in vivo. Am J Res Crit Care Med 117 Abstract issue (2008) A38
34. Cronstein N. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 76 (1994) 5-13
35. Cristalli G., Vittori S., Thompson R.D., Padgett W.L., Shi D., Daly J.W., et al. Inhibition of platelet aggregation by adenosine receptor agonists. Naunyn-Schmiedeberg's Arch Pharmacol 349 (1994) 644-650
36. Mohsenin A., Tiejuan M., Xia Y., Kellems R.E., Chen J.-F., and Blackburn M.R. Genetic removal of the A2A adenosine receptor enhances pulmonary inflammation, mucin production and angiogenesis in adenosine deaminase-deficient mice. Am J Physiol Lung Cell Mol Physiol 293 (2007) L753-L761
37. Bursock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22 (2002) 364-373
38. Dubey R.K., Gillespie D.G., and Jackson E.K. Adenosine inhibits collagen and total protein synthesis in vascular smooth muscle cells. Hypertension 33[part II] (1999) 190-194
39. Dubey R.K., Gillespe D.G., and Jackson E.K. Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptor. Hypertension 31 (1998) 516-521
40. Takiguchi Y., Nagano M., Ikada Y., and Nakashima M. Early administration of YT-146, an adenosine A2 receptor agonist, inhibits neointimal thickening after rat femoral artery endothelium injury. Eur J Pharmacol 281 (1995) 205-207
41. Nootens M., Schrader B., Kaufmann E., Vestal R., Long W., and Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 107 (1995) 54-57
42. Brett S.J., Simon J., Gibbs R., Pepper J.R., and Evans T.W. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Thorax 51 (1996) 89-91
43. Pearl R.G. Adenosine produces pulmonary vasodilation in the perfused rabbit lung via an adenosine A2 receptor. Anesth Analg 79 (1994) 46-51
44. El-Kashef H., Elmazar M.M., Al-Shabanah O.A., and Al-Bekairi A.M. Effect of adenosine on pulmonary circulation of rabbits. Gen Pharmacol 32 (1999) 307-313
45. Patterson K.W., Deb B., Kavanagh B.P., and Pearl R.G. Inhaled nitric oxide potentiates actions of adenosine but not of sodium nitroprusside in experimental pulmonary hypertension. Pharmacology 58 (1999) 246-251
46. Aranda M., Bradford K.K., and Pearl R.G. Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension. Anesth Analg 89 (1999) 152-158
47. Saadjian A.Y., Paganelli F., Gaubert M.L., Levy S., and Guieu R.P. Adenosine plasma concentration in pulmonary hypertension. Cardiovasc Res 43 (1999) 228-236
48. Saadjian A.Y., Paganelli F., Juin M.-A., Devaux C., Levy S., and Guieu R.P. Plasma beta-endorphin and adenosine concentrations in pulmonary hypertension. Am J Cardiol 85 (2000) 858-863
49. Ng C., Franklin O., Vaidya M., Pierce C., and Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr Crit Care Med 5 (2004) 10-13
50. Patole S., Lee J., and Whitehall J. Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension. Indian Pediatr 36 (1999) 307-310
51. Fullerton D.A., Jaggers J., Jones S.D., Brown J.M., and McIntyre Jr. R.C. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg 62 (1996) 874-877
52. Fullerton D.A., Jones S.D., Grover F.L., and McIntyre Jr. R.C. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 61 (1996) 1118-1123
53. Schrader J. Formation and metabolism of adenosine and adenine nucleotides in cardiac tissue. In: Phillis J.W. (Ed). Adenosine and adenine nucleotides as regulators of cellular function (1991), CRC Press, Coca Raton, FL 55-59
54. Geiger J.D., Padua R.A., and Nagy J.I. Adenosine deaminase regulation of purine actions. In: Phillis J.W. (Ed). Adenosine and adenine nucleotides as regulators of cellular function (1991), CRC Press, Coca Raton, FL 71-84
55. Shaff A.J., Wilson D.K., and Quiocho F.A. Refined 2.5 Å structure of murine adenosine deaminase at pH 6.0. J Mol Biol 226 (1992) 917-921
56. Kaul A., Chandra M., and Misra M.K. Erythrocyte adenosine deaminase a marker of reperfusion injury in patients with myocardial infarction. Int J Cardiol 115 (2007) 274-275
57. Adanin S., Yalovetskiy I.V., Nardulli B.A., Sam A.D., Jonjev Z.S., and Law W.R. Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am J Physiol Regul Integr Comp Physiol 282 (2002) R1324-R1332
58. Tang R.B., Ma C.S., Dong J.Z., Liu X.P., and Liu X. Does adenosine deaminase plays a key role in coronary artery disease. Med Hypothesis 6 7 (2006) 371-374
59. Xia Y., Khatchikian G., and Zweier J.L. Adenosine deaminase inhibition prevents free radical-mediated injury in the post ischemic heart. J Biol Chem 227 (1996) 10096-10102
60. Hostetter M.K., and Johnson G.M. The erythrocyte instigator of inflammation: generation of amidated C3 by erythrocyte adenosine deaminase. J Clin Invest 84 (1989) 665-671
61. Chen E.H., Tartaglia A.P., and Mitchell B.S. Hereditary overexpression of adenosine deaminase in erythrocytes: evidence for a cis-acting mutation. Am J Mum Genet 53 (1993) 889-893
62. Canpolat F., Unver M., Eskioglu F., Kosebalaban S., and PelinDurmazlar S.P.K. Serum and erythrocyte adenosine deaminase activities in patients with Behcet's disease. Int J Dermat 45 (2006) 1053-1056
63. Erkilic K., Evereklioglu C., Cekmen M., Ozkiris A., Duygulu F., and Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behcet's disease: original contribution/clinical and laboratory investigations. Mediators Inflamm 12 (2003) 107-116
64. Seoane L., Shellito J., Welsh D., and Deboisblanc B.P. Pulmonary hypertension associated with HIV infection. South Med J 94 (2001) 635-639
65. Cowan M.J., Brady R.O., and Widder K.J. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 83 (1986) 1089-1091
66. Sen S., Hoffman G.C., Stowe N.T., Smeby R.R., and Bumpus F.M. Erythrocytosis in spontaneously hypertensive rats. J Clin Invest 51 (1972) 710-714
67. Suno M., Shibota M., and Nagaoka A. Effect of CV-2619 (idebenone) on the half-life and hemolysis of red blood cell in strok-prone spontaneously hypertensive rats (SHRSP). Nippon Yakurigaku Zasshi 84 (1984) 407-410
68. Castillo-Melendez M., Jarrott B., and Lawrence A.J. Markers of adenosine removal in normotensive and hypertensive rat nervous tissue. Hypertension 28 (1996) 1026-1033
69. Jackson E.K., Kholer M., Mi Z., Dubey K.R., Tofovic S.P., Carcillo J.A., et al. Adenosine in vascular biology: emerging concepts. J Hypertens 14 (1996) 19-29
70. Tofovic S.P., Kusaka I., Li P., and Jackson E.K. Effects of adenosine deaminase inhibition on blood pressure in old spontaneously hypertensive rats. Clin Exp Hypertens 20 (1998) 329-344
71. Tofovic S.P., Branch R.A., Oliver D.R., Magee D.W., and Jackson E.K. Caffeine potentiates vasodilator-induced renin release. J Pharmacol Exp Ther 256 (1996) 850-860
72. Giblett E.L., Anderson J.E., Cohen F., Pollara B., and Meuwissen H.J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2 786 (1972) 1967-1969
73. Tofovic S.P., Zacharia L., Carcillo J.A., and Jackson E.K. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. Sock 16 (2001) 196-2002
74. Cohen E.S., Law W.R., Easington C.R., Cruz K.Q., Nardulli B.A., Balk R.A., et al. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am J Respir Crit Care Med 166 (2002) 16-20
75. Turhan A., Weiss L.A., Mohandas N., Coller B.S., and Frenette P.S. Primary role for adherent leukocytes in suckle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 99 (2002) 3047-3051
76. Frenette P.S., and Atweh G.F. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 117 (2007) 850-858
77. De Bruijne A.W., and Van Steveninck J. The influence of dimethylsulfoxide on the red cell membrane. Biochem Pharmacol 23 (1974) 3247-3258
78. Norred W.P., Ansel H.C., Roth I.L., and Pfeifer J.J. Mechanism of dimethyl sulfoxide-induced hemolysis. J Pharm Sci 59 (1970) 618-622
79. Jackson E.K., Mi Z., Koehler M.T., Carcillo C.A., and Herzer W. Injured erythrocytes releases adenosine deaminase into circulation. JEPT 279 (1996) 1250-1260
80. Arch J.R., and Newsholme E.A. Activities and some properties of adenylate cyclase and phosphodiesterase in muscle, liver nervous system from vertebrates and invertebrates in relation to the control of the concentration of adenosine 3′:5′-cyclic monophosphate. Biochem J 158 (1976) 603-622
81. Connor K.W., and Ashwood Smith M.J. Ineffectiveness of dymethylsulfone as ecryoprotectant agent. Cryobiology 10 (1973) 87-88